You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluphenazine
Accession NumberDB00623  (APRD00633)
TypeSmall Molecule
GroupsApproved
DescriptionA phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine. [PubChem]
Structure
Thumb
Synonyms
1-(2-Hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine
10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine
10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine
2-(4-(3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol
2-(Trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine
4-(3-(-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol
4-(3-(2-Trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol
Flufenazina
Fluorfenazine
Fluorophenazine
Fluorphenazine
Fluphenazin
Fluphénazine
Fluphenazinum
Triflumethazine
External Identifiers
  • SQ 10733
  • Squibb 16144
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FluphenazineTablet2 mgOralAa Pharma Inc1977-12-31Not applicableCanada
FluphenazineTablet1 mgOralAa Pharma Inc1977-12-31Not applicableCanada
FluphenazineTablet5 mgOralAa Pharma Inc1977-12-31Not applicableCanada
Fluphenazine 1 Tab 1mgTablet1 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 2 Tab 2mgTablet2 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine 5 Tab 5mgTablet5 mgOralPro Doc Limitee1982-12-312010-07-13Canada
Fluphenazine Decanoate Injection B.P.Liquid25 mgIntramuscular; SubcutaneousHospira Healthcare CorporationNot applicableNot applicableCanada
Fluphenazine Decanoate Injection B.P.Liquid100 mgIntramuscular; SubcutaneousHospira Healthcare CorporationNot applicableNot applicableCanada
Fluphenazine Decanoate Injection, USPSolution25 mgIntramuscular; SubcutaneousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Fluphenazine OmegaLiquid25 mgIntramuscular; SubcutaneousOmega Laboratories Ltd1999-05-28Not applicableCanada
Fluphenazine OmegaLiquid100 mgIntramuscular; SubcutaneousOmega Laboratories Ltd2000-11-20Not applicableCanada
Modecate ConcentrateLiquid100 mgIntramuscular; SubcutaneousBristol Myers Squibb Canada1990-12-31Not applicableCanada
Modecate Inj 25mg/mlLiquid25 mgIntramuscularSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1976-12-312004-08-05Canada
Moditen Enanthate Inj 25mg/mlLiquid25 mgIntramuscularSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1968-12-312003-07-28Canada
Moditen HCl Tab 10mgTablet10 mgOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1985-12-312003-07-28Canada
PMS Fluphenazine Tab 1mgTablet1 mgOralPharmascience Inc1992-12-31Not applicableCanada
PMS Fluphenazine Tab 2mgTablet2 mgOralPharmascience Inc1992-12-31Not applicableCanada
PMS Fluphenazine Tab 5mgTablet5 mgOralPharmascience Inc1992-12-31Not applicableCanada
PMS-fluphenazine DecanoateLiquid100 mgIntramuscular; SubcutaneousPharmascience Inc2000-08-31Not applicableCanada
PMS-fluphenazine Decanoate Inj (bp) 25mg/mlLiquid25 mgIntramuscular; SubcutaneousPharmascience Inc1994-12-31Not applicableCanada
PMS-fluphenazine Elixir 0.5mg/mlElixir.5 mgOralPharmascience Inc1996-10-162008-11-07Canada
Rho-fluphenazine Decanoate Inj-25mg/ml Im ScSolution25 mgIntramuscular; SubcutaneousRhodiapharm Inc1996-11-282004-07-30Canada
Rho-fluphenazine Decanoate Inj.conc-100mg/mlSolution100 mgIntramuscular; SubcutaneousRhodiapharm Inc1996-11-282004-07-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Fluphenazine Tab 2.5mgTablet2.5 mgOralApotex Inc1977-12-31Not applicableCanada
Apo-fluphenazine InjectableLiquid25 mgIntramuscular; SubcutaneousApotex Inc2001-10-052013-08-02Canada
Fluphenazine DecanoateInjection, solution25 mg/mLIntramuscular; SubcutaneousPar Pharmaceutical, Inc.2014-07-09Not applicableUs
Fluphenazine DecanoateInjection25 mg/mLIntramuscular; SubcutaneousWest Ward Pharmaceuticals Corp1996-08-30Not applicableUs
Fluphenazine DecanoateInjection, solution25 mg/mLIntramuscular; SubcutaneousTYA Pharmaceuticals2010-12-15Not applicableUs
Fluphenazine DecanoateInjection, solution25 mg/mLIntramuscular; SubcutaneousFresenius Kabi USA, LLC2010-12-15Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralSandoz Inc1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralTYA Pharmaceuticals1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine HydrochlorideSolution, concentrate5 mg/mLOralPharmaceutical Associates, Inc.2010-09-01Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralMylan Institutional Inc.1998-06-04Not applicableUs
Fluphenazine HydrochlorideTablet1 mg/1OralREMEDYREPACK INC.2011-07-11Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2009-10-30Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralSandoz Inc1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralREMEDYREPACK INC.2016-08-02Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine HydrochlorideInjection, solution2.5 mg/mLIntramuscularTYA Pharmaceuticals2010-12-28Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralMylan Institutional Inc.1998-07-15Not applicableUs
Fluphenazine HydrochlorideElixir.5 mg/mLOralPharmaceutical Associates, Inc.2010-08-31Not applicableUs
Fluphenazine HydrochlorideTablet5 mg/1OralREMEDYREPACK INC.2011-10-25Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralSandoz Inc1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine HydrochlorideInjection, solution2.5 mg/mLIntramuscularAPP Pharmaceuticals, LLC2010-12-28Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralREMEDYREPACK INC.2010-03-26Not applicableUs
Fluphenazine HydrochlorideTablet1 mg/1OralREMEDYREPACK INC.2011-08-022016-10-13Us
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralAmerican Health Packaging2014-10-13Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-09-26Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralREMEDYREPACK INC.2016-07-07Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralMylan Institutional Inc.1998-04-30Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated1 mg/1OralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralSandoz Inc1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-04-11Not applicableUs
Fluphenazine HydrochlorideTablet2.5 mg/1OralREMEDYREPACK INC.2011-06-03Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralLannett Company, Inc.2010-09-27Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralAmerican Health Packaging2015-03-31Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralClinical Solutions Wholesale, Llc1988-08-12Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralREMEDYREPACK INC.2016-07-29Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralMylan Institutional Inc.1998-06-02Not applicableUs
Fluphenazine HydrochlorideTablet, film coated5 mg/1OralClinical Solutions Wholesale1987-10-16Not applicableUs
Fluphenazine HydrochlorideTablet, film coated2.5 mg/1OralClinical Solutions Wholesale, Llc2010-09-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnatensolBristol-Myers Squibb
Dapotum DNot Available
FludecasinTanabe Mitsubishi Pharma
FludecateRafa
FlumezinTanabe Mitsubishi Pharma
FunazineJohnson
LyogenLundbeck
Lyogen DepotLundbeck
Lyogen RetardLundbeck
MetotenHemofarm
ModecateBristol-Myers Squibb
ModitenBristol-Myers Squibb
Moditen DepoKrka
PermitilNot Available
ProlixinBristol-Myers Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Fluphenazine decanoate
5002-47-1
Thumb
  • InChI Key: VIQCGTZFEYDQMR-UHFFFAOYSA-N
  • Monoisotopic Mass: 591.310632972
  • Average Mass: 591.771
DBSALT000776
Fluphenazine dihydrochloride
146-56-5
Thumb
  • InChI Key: MBHNWCYEGXQEIT-UHFFFAOYSA-N
  • Monoisotopic Mass: 509.128223252
  • Average Mass: 510.443
DBSALT000288
Fluphenazine enanthate
2746-81-8
Thumb
  • InChI Key: LRWSFOSWNAQHHW-UHFFFAOYSA-N
  • Monoisotopic Mass: 549.26368278
  • Average Mass: 549.691
DBSALT000777
Fluphenazine hydrochloride
ThumbNot applicableDBSALT001197
Categories
UNIIS79426A41Z
CAS number69-23-8
WeightAverage: 437.522
Monoisotopic: 437.174867774
Chemical FormulaC22H26F3N3OS
InChI KeyPLDUPXSUYLZYBN-UHFFFAOYSA-N
InChI
InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2
IUPAC Name
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C(F)(F)F)CC1
Pharmacology
IndicationFor management of manifestations of psychotic disorders.
Structured Indications
PharmacodynamicsFluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionFluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
CalmodulinProteinunknown
inhibitor
HumanP62158 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineFluphenazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineFluphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineFluphenazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineFluphenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Fluphenazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Fluphenazine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Fluphenazine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Fluphenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Fluphenazine.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Fluphenazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Fluphenazine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Fluphenazine.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Fluphenazine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Fluphenazine.Approved, Illicit, Investigational
AlprenololFluphenazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Fluphenazine.Approved, Investigational
AmiodaroneThe metabolism of Fluphenazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Fluphenazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Fluphenazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amperozide.Experimental
AmphetamineFluphenazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Aop200704Fluphenazine may increase the hypotensive activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Fluphenazine.Approved
ApomorphineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluphenazine.Approved, Investigational
ArotinololFluphenazine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Fluphenazine.Approved, Investigational
ArtemetherThe serum concentration of Fluphenazine can be increased when it is combined with Artemether.Approved
ArtemisininThe serum concentration of Fluphenazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Fluphenazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Fluphenazine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Fluphenazine.Approved
AtomoxetineThe metabolism of Fluphenazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Fluphenazine can be increased when it is combined with Atovaquone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Fluphenazine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Azaperone.Vet Approved
AzelastineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Barbital.Illicit
BefunololFluphenazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzocaine.Approved
BenzphetamineFluphenazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Fluphenazine.Approved, Vet Approved
BetaxololThe metabolism of Fluphenazine can be decreased when combined with Betaxolol.Approved
Betulinic AcidThe serum concentration of Fluphenazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololFluphenazine may increase the hypotensive activities of Bevantolol.Approved
BezitramideFluphenazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololFluphenazine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Fluphenazine.Approved
BopindololFluphenazine may increase the hypotensive activities of Bopindolol.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Fluphenazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Fluphenazine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Brotizolam.Approved, Withdrawn
BucindololFluphenazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolFluphenazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fluphenazine.Approved, Investigational
BupranololFluphenazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Fluphenazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Fluphenazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Fluphenazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Fluphenazine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Fluphenazine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Fluphenazine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Fluphenazine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Fluphenazine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Fluphenazine.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Fluphenazine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Fluphenazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Carisoprodol.Approved
CarteololFluphenazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolFluphenazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Fluphenazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololFluphenazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Fluphenazine.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Fluphenazine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Fluphenazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Fluphenazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorphenamine.Approved
ChlorphentermineFluphenazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Fluphenazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Fluphenazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Fluphenazine.Approved
CinacalcetThe metabolism of Fluphenazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Fluphenazine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Fluphenazine.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Fluphenazine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Fluphenazine.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Fluphenazine.Approved
ClemastineThe metabolism of Fluphenazine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Fluphenazine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Fluphenazine.Approved, Investigational
ClomipramineThe metabolism of Fluphenazine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Fluphenazine.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Fluphenazine.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Fluphenazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Fluphenazine.Approved
CobicistatThe serum concentration of Fluphenazine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Fluphenazine.Approved
CocaineThe metabolism of Fluphenazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Fluphenazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Fluphenazine.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Fluphenazine.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Fluphenazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclobenzaprine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Fluphenazine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluphenazine.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Fluphenazine.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Fluphenazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Fluphenazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Fluphenazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Fluphenazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Fluphenazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Fluphenazine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Fluphenazine.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Fluphenazine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Fluphenazine.Approved
DelavirdineThe metabolism of Fluphenazine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desflurane.Approved
DesipramineThe metabolism of Fluphenazine can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Fluphenazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Fluphenazine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineFluphenazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Fluphenazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Fluphenazine.Approved, Illicit, Vet Approved
DiethylpropionFluphenazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Fluphenazine.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Fluphenazine.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Fluphenazine.Approved
DihydroartemisininThe serum concentration of Fluphenazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluphenazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Fluphenazine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Fluphenazine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Fluphenazine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Fluphenazine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Fluphenazine.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Fluphenazine.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Fluphenazine.Approved, Investigational
DoxycyclineThe serum concentration of Fluphenazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Fluphenazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Illicit
DronedaroneThe metabolism of Fluphenazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Fluphenazine can be decreased when combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Fluphenazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Fluphenazine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Fluphenazine.Approved, Investigational
EliglustatThe metabolism of Fluphenazine can be decreased when combined with Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Fluphenazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Entacapone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Fluphenazine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Fluphenazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluphenazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Fluphenazine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Fluphenazine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Fluphenazine.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.Approved, Investigational
EsmololFluphenazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Fluphenazine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Fluphenazine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Fluphenazine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Fluphenazine.Approved
EthanolFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluphenazine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Fluphenazine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluphenazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Fluphenazine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Fluphenazine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Fluphenazine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Fluphenazine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Fluphenazine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Fluphenazine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Fluphenazine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flupentixol.Approved, Withdrawn
FlurazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Fluphenazine.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Fluphenazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Fluphenazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Fluphenazine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Fluphenazine.Approved
GepironeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Fluphenazine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Fluphenazine.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Fluphenazine can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Fluphenazine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Hexobarbital.Approved
HydrocodoneFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Fluphenazine.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Fluphenazine.Approved, Illicit
Hydroxyamphetamine hydrobromideFluphenazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Fluphenazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Fluphenazine.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Fluphenazine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Fluphenazine.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Fluphenazine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Fluphenazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Indalpine.Investigational, Withdrawn
IndenololFluphenazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Fluphenazine.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Fluphenazine.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Fluphenazine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Fluphenazine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Fluphenazine can be decreased when combined with Isoniazid.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Fluphenazine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Fluphenazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Fluphenazine.Approved, Investigational
LabetalolFluphenazine may increase the hypotensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Fluphenazine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Fluphenazine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Fluphenazine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Fluphenazine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Fluphenazine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Fluphenazine.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Fluphenazine.Approved, Investigational
LevobunololFluphenazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Fluphenazine.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Fluphenazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Fluphenazine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Fluphenazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Fluphenazine.Approved, Investigational
LisdexamfetamineFluphenazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Fluphenazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Fluphenazine.Approved
LopinavirThe metabolism of Fluphenazine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Fluphenazine.Approved
LorcaserinThe metabolism of Fluphenazine can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Fluphenazine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluphenazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lu AA21004.Investigational
LumefantrineThe serum concentration of Fluphenazine can be increased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Fluphenazine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Fluphenazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Melperone.Approved
MephedroneFluphenazine may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineFluphenazine may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine.Approved, Illicit
MequitazineFluphenazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Metaxalone.Approved
MethadoneThe metabolism of Fluphenazine can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineFluphenazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluphenazine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Fluphenazine.Approved
MethotrimeprazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Fluphenazine.Approved, Vet Approved
MetipranololFluphenazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Fluphenazine.Approved, Investigational
MetyrosineFluphenazine may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Fluphenazine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Fluphenazine.Approved
MirtazapineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Fluphenazine.Approved, Investigational
MizoribineThe serum concentration of Fluphenazine can be increased when it is combined with Mizoribine.Investigational
MMDAFluphenazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluphenazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Fluphenazine.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluphenazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Fluphenazine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Fluphenazine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Fluphenazine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Fluphenazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Fluphenazine.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Fluphenazine.Approved
NevirapineThe metabolism of Fluphenazine can be decreased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Fluphenazine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Fluphenazine.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Fluphenazine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Fluphenazine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Fluphenazine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Nortriptyline.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Fluphenazine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Fluphenazine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Opium.Approved, Illicit
OrphenadrineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Fluphenazine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Fluphenazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Fluphenazine.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Fluphenazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Fluphenazine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Fluphenazine.Approved
Peginterferon alfa-2bThe serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololFluphenazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Fluphenazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Fluphenazine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Fluphenazine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Fluphenazine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Phenoxyethanol.Approved
PhentermineFluphenazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Fluphenazine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pimozide.Approved
PindololFluphenazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Fluphenazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Fluphenazine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Fluphenazine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Fluphenazine.Approved
PractololFluphenazine may increase the hypotensive activities of Practolol.Approved
PramipexoleFluphenazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Fluphenazine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Fluphenazine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Fluphenazine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Fluphenazine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Fluphenazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Prilocaine.Approved
PrimaquineThe serum concentration of Fluphenazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Fluphenazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Fluphenazine.Approved, Vet Approved
ProguanilThe serum concentration of Fluphenazine can be increased when it is combined with Proguanil.Approved
PromazineThe metabolism of Fluphenazine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Fluphenazine.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Fluphenazine.Approved
PSD502The risk or severity of adverse effects can be increased when Fluphenazine is combined with PSD502.Investigational
PseudoephedrineFluphenazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PyrimethamineThe serum concentration of Fluphenazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Fluphenazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Fluphenazine.Approved
QuinacrineThe serum concentration of Fluphenazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine.Approved
QuinidineThe metabolism of Fluphenazine can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Fluphenazine can be increased when it is combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Fluphenazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Fluphenazine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Fluphenazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Fluphenazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Fluphenazine.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Fluphenazine.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Fluphenazine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Fluphenazine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Fluphenazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ritanserin.Investigational
RitobegronFluphenazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Fluphenazine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Fluphenazine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Fluphenazine.Approved
RolapitantThe metabolism of Fluphenazine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Fluphenazine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Romifidine.Vet Approved
RopiniroleFluphenazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fluphenazine.Approved
RotigotineFluphenazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Fluphenazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Fluphenazine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Fluphenazine is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Fluphenazine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Fluphenazine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluphenazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Fluphenazine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Fluphenazine.Approved
SertindoleThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Fluphenazine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Fluphenazine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Fluphenazine.Approved
SinefunginThe serum concentration of Fluphenazine can be increased when it is combined with Sinefungin.Experimental
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Fluphenazine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Fluphenazine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Fluphenazine.Approved, Investigational
SotalolFluphenazine may increase the hypotensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Fluphenazine.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Fluphenazine.Experimental
StiripentolThe metabolism of Fluphenazine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sufentanil.Approved, Investigational
SulfadoxineThe serum concentration of Fluphenazine can be increased when it is combined with Sulfadoxine.Approved
SulfametopyrazineThe serum concentration of Fluphenazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulpirideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Fluphenazine.Approved, Investigational
SuvorexantFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Fluphenazine.Approved, Investigational
tafenoquineThe serum concentration of Fluphenazine can be increased when it is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Fluphenazine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Fluphenazine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fluphenazine.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluphenazine.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Fluphenazine.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Fluphenazine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Fluphenazine.Approved
TerbinafineThe metabolism of Fluphenazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Fluphenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tetrodotoxin.Investigational
ThalidomideFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Fluphenazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Fluphenazine.Approved
TiclopidineThe metabolism of Fluphenazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Fluphenazine.Approved
TipranavirThe metabolism of Fluphenazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Fluphenazine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Fluphenazine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Fluphenazine.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Fluphenazine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Fluphenazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Fluphenazine can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Fluphenazine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluphenazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Fluphenazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Fluphenazine is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Fluphenazine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Fluphenazine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Fluphenazine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Fluphenazine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Fluphenazine.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Fluphenazine.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Fluphenazine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Fluphenazine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Fluphenazine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Fluphenazine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Fluphenazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Fluphenazine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluphenazine.Approved, Investigational
ZolpidemFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Ullyot, G.E.; U.S. Patent 3,058,979; October 16, 1962; assigned to Smith Kline & French
Laboratories.

US3058979
General ReferencesNot Available
External Links
ATC CodesN05AB02
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9837
Blood Brain Barrier+0.975
Caco-2 permeable-0.5387
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor IInhibitor0.923
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5
CYP450 2C9 substrateNon-substrate0.7669
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7091
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.937
CYP450 3A4 inhibitorNon-inhibitor0.715
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7056
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8828
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8990 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9146
hERG inhibition (predictor II)Inhibitor0.8157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Teva parenteral medicines inc
  • Bristol myers squibb co
  • Apothecon inc div bristol myers squibb
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Lannett holdings inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2.5 mg
InjectionIntramuscular; Subcutaneous25 mg/mL
Injection, solutionIntramuscular; Subcutaneous25 mg/mL
ElixirOral.5 mg/mL
Injection, solutionIntramuscular2.5 mg/mL
Solution, concentrateOral5 mg/mL
TabletOral1 mg/1
TabletOral2.5 mg/1
TabletOral5 mg/1
Tablet, film coatedOral1 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral5 mg/1
LiquidIntramuscular; Subcutaneous100 mg
LiquidIntramuscular25 mg
TabletOral10 mg
TabletOral1 mg
TabletOral2 mg
TabletOral5 mg
LiquidIntramuscular; Subcutaneous25 mg
ElixirOral.5 mg
SolutionIntramuscular; Subcutaneous25 mg
SolutionIntramuscular; Subcutaneous100 mg
Prices
Unit descriptionCostUnit
Fluphenazine Omega 100 mg/ml31.2USD ml
Modecate Concentrate 100 mg/ml31.2USD ml
Pms-Fluphenazine Decanoate 100 mg/ml31.2USD ml
Fluphenazine Decanoate 25 mg/ml Solution14.0USD ml
Fluphenazine 2.5 mg/ml vial7.82USD ml
Fluphenazine Omega 25 mg/ml5.22USD ml
Prolixin 10 mg tablet3.1USD tablet
Prolixin 5 mg tablet2.38USD tablet
Fluphenazine dec 25 mg/ml vial1.92USD ml
Prolixin 2.5 mg tablet1.63USD tablet
Fluphenazine 10 mg tablet1.25USD tablet
Fluphenazine HCl 10 mg tablet1.19USD tablet
Fluphenazine 5 mg tablet0.97USD tablet
Fluphenazine HCl 5 mg tablet0.94USD tablet
Fluphenazine 2.5 mg tablet0.84USD tablet
Fluphenazine HCl 2.5 mg tablet0.79USD tablet
Fluphenazine 1 mg tablet0.55USD tablet
Fluphenazine HCl 1 mg tablet0.52USD tablet
Apo-Fluphenazine 2 mg Tablet0.24USD tablet
Apo-Fluphenazine 1 mg Tablet0.18USD tablet
Apo-Fluphenazine 5 mg Tablet0.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point224-226 (Salt)U.S. Patent 3,058,979
boiling point268-274 °C at 5.00E-01 mm HgPhysProp
water solubility31.1 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.36HANSCH,C ET AL. (1995)
logS-4.15ADME Research, USCD
pKa7.9EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.019 mg/mLALOGPS
logP4.4ALOGPS
logP3.97ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)8.21ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity117.27 m3·mol-1ChemAxon
Polarizability44.92 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.44 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-001i-2391100000-6928faa0b341426b2c11View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Thioether
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
  2. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I: Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand. 1993 Dec;88(6):395-402. [PubMed:7508675 ]
  3. Qin ZH, Weiss B: Dopamine receptor blockade increases dopamine D2 receptor and glutamic acid decarboxylase mRNAs in mouse substantia nigra. Eur J Pharmacol. 1994 Sep 15;269(1):25-33. [PubMed:7828655 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Van Kampen JM, Stoessl AJ: Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. Neuroscience. 2000;101(3):629-35. [PubMed:11113312 ]
  3. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405 ]
  4. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. [PubMed:11873706 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Mongin AA, Cai Z, Kimelberg HK: Volume-dependent taurine release from cultured astrocytes requires permissive [Ca(2+)](i) and calmodulin. Am J Physiol. 1999 Oct;277(4 Pt 1):C823-32. [PubMed:10516112 ]
  2. Kawai M, Nakashima A, Ueno M, Ushimaru T, Aiba K, Doi H, Uritani M: Fission yeast tor1 functions in response to various stresses including nitrogen starvation, high osmolarity, and high temperature. Curr Genet. 2001 May;39(3):166-74. [PubMed:11409178 ]
  3. Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848 ]
  4. Nakabayashi H, Komada H, Yoshida T, Takanari H, Izutsu K: Lymphocyte calmodulin and its participation in the stimulation of T lymphocytes by mitogenic lectins. Biol Cell. 1992;75(1):55-9. [PubMed:1515867 ]
  5. Kauss H: Sensing of volume changes by poterioochromonas involves a ca-regulated system which controls activation of isofloridoside-phosphate synthase. Plant Physiol. 1981 Aug;68(2):420-4. [PubMed:16661928 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23